From human pathogen to protector: Recent advances in the immunogenic potential of pneumococcal-derived extracellular membrane vesicles (EMVs)
Asia-Pacific Journal of Molecular Biology and Biotechnology · 30.06.2026 · 206
DOI: 10.35118/apjmbb.2026.034.2.18 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asia-Pacific Journal of Molecular Biology and Biotechnology, online erschienen am 30.06.2026. Verfasst von Nurul Anis Johari und 9 weiteren Autor:innen. Die Arbeit nennt 45 Literaturangaben.
Abstract (Originalsprache)
Streptococcus pneumoniae is a significant human pathogen globally, associated with various pneumococcal infections, implicated in conditions such as pneumonia, meningitis, otitis media and sepsis. The pathogen employs numerous virulence factors, such as capsular polysaccaharide (CPS), choline binding protein (CBP), lipoproteins and pneumolysin, to engage with and evade host immune response. Recent studies have emphasised the significance of extracellular membrane vesicles (EMVs) in pathogenesis and immunity, making them potential targets for innovative treatment and vaccination approaches. This review provides a comprehensive overview of EMVs derived from S. pneumoniae and delves into their immunogenic potential as a promising novel vaccine candidate against pneumococcal infections. This review describes the mechanisms of EMVs biogenesis, their various immunogenic properties and their capability to influence host immune responses. This review synthesises findings of the past 10 years (2014-2024) regarding S. pneumoniae EMVs, emphasising their biogenesis, composition, immunogenic properties and roles in host-pathogen interactions. Besides, this review also elaborates on EMV-based vaccines and the challenges associated with their advancement. The research underscores the diverse functions of EMVs derived from S. pneumoniae in pathogenesis, encompassing biofilm formation, immunological evasion and host cell damage. EMVs exhibit strong immunogenic characteristics capable of provoking both innate and adaptive immune responses. Pre-clinical studies have indicated EMVs as a broad-spectrum vaccination candidate, overcoming the constraints of existing serotype-specific vaccines. Nonetheless, challenges such as variations in EMVs’ composition, safety issues and production scalability persist as considerable barriers. EMVs are promising strategies in the global control of pneumococcal infections because of their ability to elicit cross-serotype immunity, yet further study is required to solve safety and manufacturing issues.
Zitieren
APA
Johari, N. A., Anuar, N. F. Z., Nor, F. M., Desa, M. N. M., Wong, E. H., Mariappan, V., Vellasamy, K. M., Khan, N. L. A., Hussaini, J., & P, N. K. (2026). From human pathogen to protector: Recent advances in the immunogenic potential of pneumococcal-derived extracellular membrane vesicles (EMVs). Asia-Pacific Journal of Molecular Biology and Biotechnology, 206. https://doi.org/10.35118/apjmbb.2026.034.2.18
Vancouver
Johari NA, Anuar NFZ, Nor FM, Desa MNM, Wong EH, Mariappan V, et al. From human pathogen to protector: Recent advances in the immunogenic potential of pneumococcal-derived extracellular membrane vesicles (EMVs). Asia-Pacific Journal of Molecular Biology and Biotechnology. 2026:206. doi:10.35118/apjmbb.2026.034.2.18
BibTeX
@article{Johari2026,
author = {Johari, Nurul Anis and Anuar, Nurul Fathiyah Zaipul and Nor, Fadzilah Mohd and Desa, Mohd Nasir Mohd and Wong, Eng Hwa and Mariappan, Vanitha and Vellasamy, Kumutha Malar and Khan, Norhayati Liaqat Ali and Hussaini, Jamal and P, Navindra Kumari},
title = {From human pathogen to protector: Recent advances in the immunogenic potential of pneumococcal-derived extracellular membrane vesicles (EMVs)},
journal = {Asia-Pacific Journal of Molecular Biology and Biotechnology},
year = {2026},
pages = {206},
doi = {10.35118/apjmbb.2026.034.2.18}
}
EUVIMED